2HG MRS was performed in 136 patients using point-resolved spectroscopy at 3 T in parallel with standard clinical magnetic resonance imaging and assessment. Data were analyzed in patient cohorts ...

Identifying key molecular drivers of survival and therapeutic targets in glioblastoma through integrated transcriptomic analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Every week, Harvard Medical School neuro-oncologist Annie Hsieh treats patients with gliomas—the most common type of brain cancer, including the deadliest, glioblastoma. After Hsieh's neurosurgeon ...

Isocitrate dehydrogenase (IDH)-mutant gliomas happen when IDH1 or IDH2 changes create an abnormal enzyme. This mutant enzyme makes D-2 hydroxyglutarate (D-2HG), which encourages tumor growth.

Chimerix, Inc. (CMRX) announced that the FDA had accepted for review its New Drug Application [NDA] of dordaviprone for the treatment of patients with recurrent H3 K27M-mutant diffuse glioma. Not only ...